¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cardiac gated MR study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
  • single blind study
    ´ÜÀϸͰ˿¬±¸
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
  • video-urodynamic study
    ¿µ»ó¿ä¿ªµ¿Çа˻ç
  • advanced cardiac life support
    »ó±Þ½ÉÀå¼Ò»ý¼ú, Àü¹®½ÉÀå¼Ò»ý¼ú
  • absolute cardiac dullness
    Àý´ë½ÉÀåµÐŹÀ½
  • cardiac
    1. ½ÉÀå- 2. µé¹®-, ºÐ¹®- 3. ½ÉÀ庴ȯÀÚ
  • cardiac arrest
    ½ÉÀåÁ¤Áö
  • cardiac arrhythmia
    ½ÉÀåºÎÁ¤¸Æ
  • cardiac asthma
    ½ÉÀåõ½Ä
  • cardiac beriberi
    ½ÉÀå°¢±â
  • cardiac catheterization
    ½ÉÀåµµ°ü»ðÀÔ, ½ÉÀåÄ«Å×ÅÍ»ðÀÔ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pilot study
    ¿¹ºñ½ÇÇè
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • professional activity study
    Àü¹®°¡È°µ¿¿¬±¸
  • prospective study
    °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • study
    ¿¬±¸, °Ë»ç
  • single blind study
    ´ÜÀϸͰ˹ý
  • survivorship study
    »ýÁ¸¿¬±¸
  • time study
    ½Ã°£¿¬±¸
  • tracer study
    ÃßÀûÀÚ¿¬±¸
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reduction of cardiac work load
    ½ÉÀÛ¾÷·®ÀÇ °æ°¨(ãýíÂåöåÖ¡­ÌîÊõ).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • time study
    ½Ã°£¿¬±¸(¡­æÚϼ).
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬?¡­æÚϼ)
  • urodynamic study
    ¿ä¿ªµ¿ÇÐ °Ë»ç
  • validity of clinical study
  • video-urodynamic study
    ºñµ¥¿À ¿ä¿ªÇа˻ç
  • water-loading study
    ¼öºÐ-ºÎÇÏ ½ÃÇè
  • absolute cardiac dullness
    Àý´ë½ÉµÐŹÀ½(ï¾ÓßãýöúëåÍ£).
  • advanced cardiac life support
    ÀÌÂ÷ (½ÉÆó)¼Ò»ý¼ú
  • axis of heart ; cardiac axis
    ½ÉÀåÃà(¡­õî).
  • axis of heart ; cardiac axis
    ½ÉÀåÃà(ãýíôõî)
  • black cardiac syndrome
    Èæ½ÉÀåÁõÈıº(ýÙãýòÅñøý¦ÏØ).
  • cardiac
    ½ÉÀåÀÇ(ãýíô- ).
  • cardiac
    1. ½ÉÀå(¼º)(ãýíôàõ)ÀÇ. 2. ºÐ¹®(ÝÄÚ¦)ÀÇ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GESICA Argentinian Study Group for the Prevention of Cardiac Insufficiency [Grupo de Estudio de la Sobrevid...
PCS palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph...
ACD absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom...
CAC cardiac-accelerator center; cardiac arrest code; circulating anticoagulant
CAS calcarine sulcus; calcific aortic stenosis; Cancer Attitude Survey; carbohydrate-active steroid; car...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
QGS Quantitative Gated SPECT
VGCC Voltage gated Ca(2+) channel
VGCC voltage gated calcium channel
VGSC voltage-gated sodium channel
ACI Acute cardiac ischemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cardiac anomaly
    ½É ÀÌ»ó, ½ÉÀå ÀÌ»ó, ½ÉÀå ±âÇü
    ½ÉÀåÀÌ ¼±ÃµÀû, À¯ÀüÀûÀÎ °áÇÔÀÇ °á°ú·Î¼­ Á¤»ó±âÁØ¿¡¼­ ¸¹ÀÌ ¶³¾îÁø °Í.
  • cardiac arrest
    ½É Á¤Áö, ½ÉÀå Á¤Áö
    ½ÉÀåÀÇ ±â´ÉÀÌ ¸ØÃß´Â °Í. ½ÉÀåÀÇ ±â´ÉÀÌ ¿ÏÀüÈ÷ Á¤ÁöµÇ´Â °Í.
  • cardiac assist
    ½É º¸Á¶
    ½ÉÀåÀ» º¸Á¶ÇÏ´Â °Í.
  • cardiac asthma
    ½ÉÀμº õ½Ä
    ÁÂ½É½Ç ºÎÀü°ú °°Àº ½ÉÀå Áúȯ¿¡ ¼ö¹ÝÇÏ¿© ÀϾ´Â ¹ßÀÛ¼º È£Èí °ï¶õ.
  • cardiac branch
    ½ÉÀå °¡Áö, ½ÉÀåÁö
    ½ÉÀå¿¡¼­ ºÐÇÒ ¶Ç´Â ÆÄ»ýÇÑ °Í.
  • cardiac catheter
    ½ÉÀå Ä«Å×ÅÍ
    X¼± Åõ½ÃÇÏ¿¡ ¸»ÃÊÇ÷°üÀ» ÅëÇÏ¿© ½É¹æ, ½É½Ç¿¡ »ðÀÔÇϵµ·Ï ¸¸µç Ư¼ö Ä«Å×ÅÍ.
  • cardiac chamber
    ½É½Ç
    µ¿ÀǾî=cardiac ventricle.
  • cardiac compensation
    ½ÉÀå ´ë»ó
    ½ÉÀå°ú °ü·ÃµÈ Áõ»óÀ» ³ªÅ¸³»Áö ¾Ê°Ô ½ÉÀåÀÌ ÀûÀýÇÑ Ç÷·ù·®À» À¯ÁöÇϰí ÀÖ´Â °Í.
  • cardiac contraction
    ½ÉÀå ¼öÃà
    ½ÉÀå±ÙÀ°ÀÇ ¼öÃà°ú °ü·ÃÇÏ¿© ´ÜÃà°ú ±äÀåÀÇ ¹ß»ýÀ» ¶æÇÑ´Ù.
  • cardiac cycle
    ½ÉÀå ÁÖ±â, ½É ÁÖ±â
    ½É¹æ°ú ½É½ÇÀº ½Ã°£ÀûÀ¸·Î µ¿½Ã´Â ¾Æ´ÏÁö¸¸ ¼öÃà°ú È®ÀåÀ» °ÅµìÇϰí ÀÖ°í, ÀÌ ÁÖ±âÀûÀΠȰµ¿ÀÌ ½É¹Úµ¿ÀÌ°í ½É¹Úµ¿ÀÇ Áֱ⸦ ½ÉÁÖ±â¶ó°í ÇÑ´Ù.
  • cardiac decompensation
    ½É´ë»ó ºÎÀü, ½É½ÇÁ¶, ½ÉÀå ½ÇÁ¶, ½É ±â´É ´ë»ó ºÎÀü
    ½ÉÀåÀÌ ´ë»ó¼º ±â´É Áï ºñ´ë³ª ºó¸Æ µîÀ¸·Î ÃæºÐÈ÷ ¼øÈ¯ Ç÷·ù·®À» À¯ÁöÇÏÁö ¸øÇÏ´Â »óÅÂ.
  • cardiac depressant
    ½É ¾ïÁ¦Á¦
    ½É¹Ú ¼öÀÇ °¨¼Ò¿Í ½ÉÀå ¼öÃà·ÂÀÇ ÀúÇϸ¦ ÀÏÀ¸Å°´Â ¾à¹°.
  • cardiac disorder
    ½ÉÀå Áúȯ
    ½ÉÀåÀÇ Àå¾Ö, ºÎÁ¶È­, Áúȯ. ±â´ÉÀÇ È¥¶õ ¶Ç´Â ºñÁ¤»ó.
  • cardiac dysfunction
    ½É ±â´É Àå¾Ö, ½ÉÀå ±â´É Àå¾Ö
    ½ÉÀåÀÇ ±â´ÉÀå¾Ö ¶Ç´Â ÀÌ»ó.
  • cardiac electrophysiology
    ½É Àü±â»ý¸®ÇÐ, ½ÉÀå Àü±â »ý¸®ÇÐ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
epidemiologic study characteristics Types and formulations of studies used in epidemiological and clinical research.
(12 Dec 1998)
twin study A method of detecting genetic causes in human traits and genetic factors in behaviour using sets of twins.
(12 Dec 1998)
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
Framingham Heart study <epidemiology> Ongoing epidemiologic study of a cohort of over 5,000 of the population of Framingham, MA conducted since 1949 under the auspices of the National Institutes of Health and Boston University.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
abnormal cleavage of cardiac valve Congenital malformation of a valve leaflet with a defect extending from the free margin.
(05 Mar 2000)
anterior cardiac veins Two or three small veins in the anterior wall of the right ventricle opening directly into the right atrium independently of the coronary sinus.
Synonym: venae cordis anteriores.
(05 Mar 2000)
area of cardiac dullness A triangular area determined by percussion of the front of the chest; it corresponds to the part of the heart that is not covered by lung tissue.
(05 Mar 2000)
cardiac <cardiology> Pertaining to the heart.
Origin: L. Cardiacus from Gr. Kardiakos
(16 Dec 1997)
cardiac accident Sudden cardiac catastrophe, such as may result from coronary occlusion.
(05 Mar 2000)
cardiac albuminuria Albuminuria caused by congestive heart failure.
(05 Mar 2000)
cardiac alternation The occurrence of any cardiac phenomenon every other beat.
(05 Mar 2000)
cardiac aneurysm Thinning, stretching, and bulging of a weakened ventricular wall, usually as a result of myocardial infarction; rarely postinflammatory or congenital.
Synonym: mural aneurysm, ventricular aneurysm.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á